✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
BIIB021 is an investigational drug.
There have been 7 clinical trials for BIIB021. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.
The most common disease conditions in clinical trials are Neoplasms, Breast Neoplasms, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Biogen and [disabled in preview].
Recent Clinical Trials for BIIB021
|Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding||Biogen||Phase 2|
|Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors||Biogen||Phase 1|
|An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)||Biogen||Phase 2|